Can ozempic and mounjaro turn back your biological clock?
NCT ID NCT07293325
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will give 66 adults with obesity either semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), or metformin for 24 weeks. Researchers will use a DNA test called iWatchAge to see if these drugs can reverse or slow the genetic signs of aging. The goal is to find out if treating obesity can also help people age more slowly at a cellular level.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide, tirzepatide, or metformin
- What this could lead to
- If it works, this could point toward a way to slow biological aging in people with obesity, potentially reducing age-related health risks.
- What could go wrong
- This is a small, early-stage study with only 66 people. It measures a biomarker (epigenetic age), not actual health outcomes, so results may not translate to real-world benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULTS WITH SIMPLE OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, China